These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 7474898)

  • 21. Carnitine disposition before and during valproate therapy in patients with epilepsy.
    Riva R; Albani F; Gobbi G; Santucci M; Baruzzi A
    Epilepsia; 1993; 34(1):184-7. PubMed ID: 8422857
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Valproate, carnitine metabolism, and biochemical indicators of liver function. Collaborative Group for the Study of Epilepsy.
    Beghi E; Bizzi A; Codegoni AM; Trevisan D; Torri W
    Epilepsia; 1990; 31(3):346-52. PubMed ID: 2111771
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Valproate induces in vitro accumulation of long-chain fatty acylcarnitines.
    Silva MF; Jakobs C; Duran M; de Almeida IT; Wanders RJ
    Mol Genet Metab; 2001 Aug; 73(4):358-61. PubMed ID: 11509020
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of L-carnitine supplementation on acute valproate intoxication.
    Murakami K; Sugimoto T; Woo M; Nishida N; Muro H
    Epilepsia; 1996 Jul; 37(7):687-9. PubMed ID: 8681902
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hepatotoxicity in rat following administration of valproic acid.
    Sugimoto T; Woo M; Nishida N; Takeuchi T; Sakane Y; Kobayashi Y
    Epilepsia; 1987; 28(2):142-6. PubMed ID: 3102219
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Carnitine transport in cultured muscle cells and skin fibroblasts from patients with primary systemic carnitine deficiency.
    Rebouche CJ; Engel AG
    In Vitro; 1982 May; 18(5):495-500. PubMed ID: 7118133
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Endocardial fibroelastosis and primary carnitine deficiency due to a defect in the plasma membrane carnitine transporter.
    Bennett MJ; Hale DE; Pollitt RJ; Stanley CA; Variend S
    Clin Cardiol; 1996 Mar; 19(3):243-6. PubMed ID: 8674264
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The decreased level of plasma carnitine in patients with epilepsy].
    Belousova ED
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(6):106-110. PubMed ID: 28745680
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impaired fatty acid oxidation in children on valproic acid and the effect of L-carnitine.
    Kossak BD; Schmidt-Sommerfeld E; Schoeller DA; Rinaldo P; Penn D; Tonsgard JH
    Neurology; 1993 Nov; 43(11):2362-8. PubMed ID: 8232957
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Carnitine in the treatment of valproic acid-induced toxicity.
    Lheureux PE; Hantson P
    Clin Toxicol (Phila); 2009 Feb; 47(2):101-11. PubMed ID: 19280426
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Carnitine metabolism and morphometric change of liver mitochondria in valproate-treated rats.
    Murakami K; Sugimoto T; Nishida N; Woo M; Araki A; Kobayashi Y; Sakane Y
    Neuropediatrics; 1990 Nov; 21(4):187-90. PubMed ID: 2290478
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Valproic acid uptake by bovine brain microvessel endothelial cells: role of active efflux transport.
    Gibbs JP; Adeyeye MC; Yang Z; Shen DD
    Epilepsy Res; 2004 Jan; 58(1):53-66. PubMed ID: 15066675
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatotoxicity in rat following administration of valproic acid: effect of L-carnitine supplementation.
    Sugimoto T; Araki A; Nishida N; Sakane Y; Woo M; Takeuchi T; Kobayashi Y
    Epilepsia; 1987; 28(4):373-7. PubMed ID: 3113926
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of Carnitine on Valproic Acid Pharmacokinetics in Rats.
    Katayama H; Mizukami K; Yasuda M; Hatae T
    J Pharm Sci; 2016 Oct; 105(10):3199-3204. PubMed ID: 27499337
    [TBL] [Abstract][Full Text] [Related]  

  • 35. L-carnitine supplementation in childhood epilepsy: current perspectives.
    De Vivo DC; Bohan TP; Coulter DL; Dreifuss FE; Greenwood RS; Nordli DR; Shields WD; Stafstrom CE; Tein I
    Epilepsia; 1998 Nov; 39(11):1216-25. PubMed ID: 9821988
    [TBL] [Abstract][Full Text] [Related]  

  • 36. L-carnitine replacement therapy in chronic valproate treatment.
    Melegh B; Kerner J; Acsádi G; Lakatos J; Sándor A
    Neuropediatrics; 1990 Feb; 21(1):40-3. PubMed ID: 2107456
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transport of carnitine into cells in hereditary carnitine deficiency.
    Eriksson BO; Gustafson B; Lindstedt S; Nordin I
    J Inherit Metab Dis; 1989; 12(2):108-11. PubMed ID: 2502670
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alteration of renal carnitine metabolism by anticonvulsant treatment.
    Camiña MF; Rozas I; Castro-Gago M; Paz JM; Alonso C; Rodriguez-Segade S
    Neurology; 1991 Sep; 41(9):1444-8. PubMed ID: 1891096
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of carnitine supplementation in valproate-induced hyperammonaemia.
    Böhles H; Sewell AC; Wenzel D
    Acta Paediatr; 1996 Apr; 85(4):446-9. PubMed ID: 8740302
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Functional characterization of the carnitine transporter defective in primary carnitine deficiency.
    Scaglia F; Wang Y; Longo N
    Arch Biochem Biophys; 1999 Apr; 364(1):99-106. PubMed ID: 10087170
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.